Why Nektar Therapeutics Shares Are Rallying 13.8% Today
After the company presented results from an early-stage study of its NKTR-214 in solid tumor cancer at the 2017 Society for Immunotherapy of Cancer (SITC) annual meeting, Nektar Therapeutics (NASDAQ: NKTR) shares are jumping 13.8% higher as of 2 p.m. EST Monday.
Nektar Therapeutics reported third-quarter financial results that helped shares rally significantly last week, and today, management unveiled promising data from a small phase 1/2 study evaluating NKTR-214 in combination with Bristol-Myers Squibb's (NYSE: BMY) Opdivo.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Nektar Therapeutics Aktie
1,25 €
3,71 %
Nektar Therapeutics sticht etwas positiv hervor mit 4 Buy- und 1 Sell-Einschätzungen.
Das Kursziel von 2 € für Nektar Therapeutics bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 1.25 €.
